Selumetinib (AZD6244) 化学構造
分子量: 457.68




Quality Control & MSDS


  • Compare MEK Inhibitors
  • 研究分野
  • Combination Therapy



製品説明 Selumetinib (AZD6244) は有効的にMEK1を抑制して、IC50 が14 nMになる.



14 nM [1]

In vitro試験 AZD6244 is not competitive with ATP and inactivates the ERK1/2 phosphorylation with IC50 concentrations below 40 nM. AZD6244 also inhibits the growth of primary HCC cells through inhibition of ERK1/2 and p90RSK phosphorylation, accompanied with elevation of the cleavage of caspase-3 and caspase-7, and cleaved poly(ADP)ribose polymerase. AZD6244 has little effects on the p38, c-Jun-NH2-kinase, phosphatidylinositol 3-kinase, and MEK5/ERK5 pathways. [1] AZD6244 is sensitive to Raf mutations in breast cancer cell lines and Ras mutations in NSCLC cell lines. [2]
In vivo試験 AZD6244 significantly inhibits phosphorylation of ERK1/2 in 2-1318, 5-1318, 26-1004 and 4-1318 xenografts and induces apoptosis in primary 2-1318 cells by activating the caspase pathway. [1] AZD6244 could inhibit the tumor growth in HT-29 xenograft, which is a colorectal tumor model carrying a B-Raf mutation, at a dose of 100 mg/kg and the tumor growth inhibition of AZD6244 is better than it of Gemcitabine. [3] Otherwise AZD6244 could inhibit HCC xenografts tumor growth, which associated with increased apoptosis and down-regulation of cell cycle regulators, including cyclin D1, Cdc-2, CDK2 and 4, cyclin B1, and c-Myc. [4]
臨床試験 AZD6244 is current in Phase II clinical trial against non-small-cell lung carcinoma (NSCLC).
特集 First MEK inhibitor being tested in Phase II clinical trials.

プロトコル (参考用のみ)



Assay of MEK Kinase Activity Anti-MEK1 antibody is used to immunoprecipitate MEK1 molecules. MEK kinase activity is measured as the ability of immuno-isolated MEK1 to activate recombinant ERK1 in a coupled assay using MBP as the end point of the assay. Phosphorylated MBP is resolved on a 14% SDS-PAGE gel and vacuum-dried before exposure to X-ray film.



細胞株 Primary HCC cell lines including 2-1318, 4-1318 and 26-1004 cells
濃度 ~ 10 μM
反応時間 24 or 48 hours

Cells are seeded at a density of 2.0 × 104. After 48 hours incubation, the cells are rinsed twice with culture media. Cells are treated with various concentrations of AZD6244 for 24 or 48 hours. Cell viability is determined by the 3-(4,5-dimethylthiazol-2y1)-2,5-diphenyltetrazolium bromide (MTT) assay. Cell proliferation is assayed using a bromodeoxyuridine kit.



動物モデル HCC xenografts in mice homozygous for the SCID (severe combined immunodeficiency) mutation
製剤 In water
投薬量 50 or 100mg/kg
投与方法 Administered via p.o.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)



Download Selumetinib (AZD6244) SDF
分子量 457.68


CAS No. 606143-52-6
保管 2年-20℃
6月-80℃in solvent
別名 ARRY-142886
溶解度 (25°C) * In vitro DMSO 91 mg/mL warming (198.82 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 4% DMSO+30% PEG 300+5% Tween 80+ddH2O 10mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 6-(4-bromo-2-chlorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide

カスタマーフィードバック (12)

Click to enlarge
Source , , Cell, 2012, 151(5): 937–950. Selumetinib (AZD6244) purchased from Selleck
Method Western Blot
Cell Lines A375 cells
Concentrations 0.5 µM
Incubation Time 6 h
Results We found that MED12KD in A375 cells caused MEK/ERK activation and conferred resistance to both PLX4032 and AZD6244.

Click to enlarge
Source , , Cell, 2012, 151(5): 937–950. Selumetinib (AZD6244) purchased from Selleck
Method Western Blot
Cell Lines SKCO-1 cells
Concentrations 0.5、1 µM
Incubation Time 6 h
Results MED12KD in SK-CO-1 (KRASV12) colorectal cancer (CRC) cells also resulted in activation of MEK/ERK and conferred resistance to AZD6244.

Click to enlarge
Source Nature, 2010, 468, 968-972. Selumetinib (AZD6244) purchased from Selleck
Method Immunoblotting
Cell Lines A375 cells
Concentrations 1 μM
Incubation Time
Results Ectopic COT expression in A375 and SKMEL28 cells also conferred decreased sensitivity to the MEK inhibitors CI-1040 and AZD6244, suggesting that COT expression alone was sufficient to induce this phenotype. In the setting of ectopic COT expression, exposure to AZD6244 or CI-1040 in combination with PLX470 (1 μM each) reduced cell growth and pERK expression more effectively than did single-agent PLX4720, even at concentrations of 10 μM.

Click to enlarge
Source Nature, 2010, 468, 973-977. Selumetinib (AZD6244) purchased from Selleck
Method Survival Assay
Cell Lines isogenic cell
Concentrations 0.01-10 μM
Incubation Time 72 h
Results The growth of M249 R4 and Pt55 R was sensitive to MEK inhibition in the presence of PLX4032

Click to enlarge
Source Proc Natl Acad Sci USA , 2009, 106, 20411-20416. Selumetinib (AZD6244) purchased from Selleck
Method Cell growth inhibition assays
Cell Lines melanoma cells
Concentrations 0.001-100 μM
Incubation Time 16 h
Results The GI50 for AZD6244 was 10-50 nM in treatment-naïve BRAFV600E melanoma cultures (WM3482, WM3457, and WM3506) but exceeded 2 μM in cells derived from the AZD6244-resistant metastasis (M307; Fig. A ). Likewise, marked biochemical inhibition of p-ERK was achieved follow ing a 16-hour exposure to 400 nM AZD6244 in treatment-naïve lines, but p-ERK remained robust in the resist ant cells even at 10 MAZD6244 (Fig. B ). Next, we introduced recombinant MEK1(P124L) into parental A375 cells and examined pharmacological resistance to MEK inhibition. As observed with the MEK1(P124S) allele above, MEK1(P124L) ex pression resulted in an ≈5-fold increase in AZD6244 GI50 when c ompared to A375, MEK-WT, or MEK-DD (Fig. C). Similarly, MEK1(P124L) conferred sustained p-ERK expression following exposure to varying concentrations of MEK inhibitor, with measureable p-ERK even at 2 μM of AZD6244 (Fig. D ). In contrast, parental A375 cells and those expressing

Click to enlarge
Source Cancer Res, 2010, 70, 4709-4718. Selumetinib (AZD6244) purchased from Selleck
Method Immunohistochemical staining and immunoblotting
Cell Lines HCT116 xenografts
Concentrations 25 mg/kg/bid
Incubation Time 21 d
Results AZD6244 significantly suppresses HCT116 colon cancer xenograft tumor growth in vivo.

Click to enlarge
Source Cancer Res, 2010, 70, 4709-4718. Selumetinib (AZD6244) purchased from Selleck
Method Immunoblotting
Cell Lines MDA-MB-435 cells, HCT116 cells, SW620 cells, HT29 cells, WM793 cells
Concentrations 10 μmol/L
Incubation Time 4 h
Results AZD6244 significantly inhibits ERK activation and increases FOXO3a expression in all these cancer cell lines, in which cell cycle arrest and apoptosis are concurrently enhanced.

Click to enlarge
Source Clin Cancer Res, 2010, 16, 6029-6039. Selumetinib (AZD6244) purchased from Selleck
Method Clonogenic assays
Cell Lines melanoma cell lines
Concentrations 5000 nM
Incubation Time
Results Combinations were more effective in inhibiting colony formation at lower concentrations than either drug alone.

Click to enlarge
Source Oncogene, 2012, 31, 3277–3286. Selumetinib (AZD6244) purchased from Selleck
Method Western Blot
Cell Lines HEK-293 cells
Concentrations 1 uM
Incubation Time
Results We cultured HEK-293 cellsstably overexpressing p37d or p110d with the general PI3K –inhibitor, LY294002, or the MAPK-inhibitor, AZD6244. The inhibitors strongly affected the levels ofphosphorylated AKT S473 and ERK.

Click to enlarge
Source Br J Haematol, 2010, 149, 537–549. Selumetinib (AZD6244) purchased from Selleck
Method [3H]thymidine uptake assay/TRAP assay
Cell Lines INA-6 MM cells, PBMCs
Concentrations 2-20000 nmol/l
Incubation Time 2/14 d
Results AS703026 inhibited growth of MM cells more potently than AZD6244 (Figs B). For example, the IC50 of AS703026 and AZD6244 against INA-6 cells was 10 and 100 nmol/l, respectively. AS703026 was also approximately 10-fold more potent than AZD6244 at inhibiting cytokine-induced osteoclast differentiation in vitro, as measured by number of TRAP-positive multinuclear cells following treatment of PBMCs with RANKL and M-CSF(Fig D).

Click to enlarge
Source Dr. Jong-In Park of Medical College of Wisconsin. Selumetinib (AZD6244) purchased from Selleck
Method Western Blot
Cell Lines A375 cells
Concentrations 0-10 μM
Incubation Time 1/24 h

Click to enlarge
Source Selumetinib (AZD6244) purchased from Selleck
Method Western Blot
Cell Lines HeLa cells
Concentrations 0/10/100/1000 nM
Incubation Time 24 h

文献中の引用 (115)



電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)


* 必須

Related MEK 阻害剤

  • Cobimetinib (GDC-0973, RG7420)

    Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM. Phase 3.

  • BI-847325

    BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor. Phase 1.

  • GDC-0623

    GDC-0623 is a potent and ATP-uncompetitive MEK1 inhibitor with Ki of 0.13 nM. Phase 1.

  • GDC-0994

    GDC-0994 is a potent, orally available ERK1/2 inhibitor. Phase 1.

  • Trametinib (GSK1120212)

    Trametinib (GSK1120212)は、非常に特定で有力なMEK1MEK2 阻害剤で、IC50 がそれぞれ 0.92 nM と 1.8 nMです。

    Features:More potent than PD0325901 or AZD6244.

  • PD0325901

    PD0325901は選択的です、そして、非ATP競争的有糸分裂促進物質はMEK活動のinhibitonのためにプロテインキナーゼ・キナーゼ(MEKまたはMAPKK)MEK阻害剤を起動させました。IC50 が 0.33 nMになる。

  • U0126-EtOH

    U0126-EtOH は化学的に合成されて非常に選択的な阻害剤で、MEK1 とMEK2 に作用すると、 IC50 がそれぞれ0.07 μM と 0.06 μMになる。

    Features:A chemically synthesized and highly selective inhibitor of both MEK1 and MEK2.

  • PD98059

    PD98059は、非競争的MEK</bです> 阻害剤で、IC50 が2 μMです.

    Features:Does not inhibit c-Raf phosphorylated MEK1.

  • PD184352 (CI-1040)

    PD184352 (CI-1040)は、ATP非競争MEK1/2阻害剤で、IC50 が 17 nMです。

    Features:First MEK inhibitor to begin clinical development.


Tags: Selumetinib (AZD6244)を買う | Selumetinib (AZD6244)供給者 | Selumetinib (AZD6244)を購入する | Selumetinib (AZD6244)費用 | Selumetinib (AZD6244)生産者 | オーダーSelumetinib (AZD6244) | Selumetinib (AZD6244)代理店
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID